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VALVULAR HEART DISEASE 
Comparison of Allografts and Prosthetic Valves 
When Used for Emergency Aortic Valve 
Replacement for Active Infective Endocarditiq 
Flavian M. Lupinetti, MD, and John H. Lemmer, Jr., MD 
Aortic valve replacement (AVR) using allografts 
is an established method of treating aortic valve 
disease. It is uncertain, however, whether the in- 
creased technical demands of allograft AVR can 
be justified in emergency operations. This study 
reports 15 patients treated between 1987 and 
1990 for acute bacterial or fungal endocarditis 
involving the aortic valve. Patients underwent 
emergency AVR because of severe congestive 
failure, overwhelming sepsis or cerebral emboli. 
Eight patients received prosthetic valves (group 
I: 4 mechanical, 4 porcine) and 7 received human 
allografts (group II: 5 aortic and 2 pulmonary). 
The groups were comparable in age (group I, 55 
years; group II, 51 years), intravenous drug 
abuse (group I, 1; group II, 3), and previous 
AVR (group I, 3; group II, 2). One group I and 4 
group II patients had septal abscesses. Addition- 
al procedures in group I included mitral valve re- 
placement (2), tricuspid valve reptacement (1) 
and aortic root replacement (1). Additional pro- 
cedures in group II were mitral valve repair (1), 
root replacement (l), atrial septal defect closure 
(1) and aortocoronary bypass (1). Mean bypass 
times (group I, 189 minutes; group II, 294 min- 
utes) and cross-clamp times (group I; 108 min- 
utes; group II, 121 minutes) were similar. Oper- 
ative deaths occurred in 4 of 8 group I and 1 of 
7 group II patients. All surviving patients have 
been successfully followed (group I, 28 months; 
group II, 18 months). No group I patient has re- 
quired reoperation. One group II patient required 
reoperation for recurrent infection affecting the 
allograft, and another group II patient died 10 
months postoperatively from noncardiac causes. 
All other group II patients are alive and well with 
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functioning allografts. AVR with allografts can 
be performed safely in this high-risk patient pop- 
ulation. 
(Am J Cardiol 1991;68:637-641) 
0 
rthotopic aortic valve replacement (AVR) us- 
ing a human valve allograft was first per- 
formed by Ross in 1962.’ Lau et al2 and Man- 
has et al3 extended this operation to the treatment of 
endocarditis. Since then, several groups have reported 
their experience with this technique.4-6 Allografts may 
be the preferred substitute for acutely infected aortic 
valves because of their resistance to infection.7-s De- 
spite the successes of allograft AVR for endocarditis, it 
is likely that most patients requiring emergency opera- 
tion in this setting are treated with prosthetic valves. It 
is possible that some surgeons question the appropriate- 
ness of performing a more technically demanding pro- 
cedure on a critically ill patient. In such a patient, the 
additional time required for proper insertion of an allo- 
graft may be thought to compromise the chances for a 
successful outcome. To evaluate these questions, we 
have reviewed our results with emergency AVR for en- 
docarditis. 
METHODS 
Patients: The records of patients undergoing AVR 
for endocarditis between 1987 and 1990 at 1 institution 
were reviewed. Patients with valvar disease resulting 
from previous endocarditis that had resolved by the 
time of operation, patients treated for an extended peri- 
od with antibiotics to permit AVR under better condi- 
tions, and patients with negative blood and valve cul- 
tures at operation were excluded from the study. All 
patients included in this series required emergency op- 
eration for 1 or more clinical criteria: intractable con- 
gestive failure, overwhelming sepsis, or documented ce- 
rebral emboli attributed to valvar vegetations. Records 
were examined for preoperative information including 
demographic data, predisposing factors to endocarditis, 
bacteriologic findings, and cardiac evaluation by echo- 
cardiography and cardiac catheterization. Operative 
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TABLE I Patient Data: Allograft Versus Prosthetic Valves for Aortic Valve Replacement for Active Infective Endocarditis 
Age W Predisposing indications for Operative Gram Stain 
Pt. No. & Sex Factors Blood Cultures Operation Findings of Valve 
Group I 
1 77 M Aortic stenosis S. aureus Congestive failure Vegetations Not performed 
2 69 F Previous AVR S. aureus Congestive failure Abscess Gram + cocci 
3 47 M i.v. drug abuse Str. sanguis Sepsis Vegetations Gram + cocci 
4 65M Aortic stenosis Str. bovis Congestive failure Vegetations Not performed 
5 47 M 0 Str. hyacis Congestive failure Vegetations Gram + cocci 
6 69F Previous AVR S. aureus Congestive failure Vegetations Not performed 
7 44M Previous AVR S. aureus Sepsis Vegetations Gram + cocci 
8 25 F i.v. drug abuse S. aureus Cerebral embolism Vegetations Gram + cocci 
Group II 
9 50 F Aplastic anemia; Str. faecalis Congestive failure Abscess 
Hickman catheter 
10 62 M Previous AVR C. albicans Sepsis Vegetations 
11 59 F Aortic stenosis Str. faecalis Cerebral embolism Vegetations 
12 62 F Atrial septal defect S. aureus Cerebral embolism Abscess 
Atrial septal defect 
13 58 F iv. drug abuse Str. faecalis Congestive failure Abscess 
14 24F Previous AVR S. aureus Congestive failure Abscess 
Aorta-RA fistula 
15 42 M i.v. drug abuse S. aureus Congestive failure Vegetations 
AVR = aortic valve replacement; C. = candida; i.v. = intravenous: RA = right atrial; S = staphylcoccus; Str. = streptococcus. 
Not performed 
Yeast forms 
Gram + cocci 
Not performed 
Gram + cocci 
Gram + cocci 
Gram + cocci 
TABLE II Operative and Postoperative Data 
Replacement Bypass 
Pt. No. Valve Duration (min) 
lschemia 
Duration (min) Other Procedures 
Operative 
Result Long-Term Result 
I Group I 
Porcine 137 100 
Porcine 220 145 
Porcine 109 60 
Mechanical 116 71 
Mechanical 211 156 
Mechanical 358 93 
Mechanical 227 158 
Porcine 130 83 
0 Died - 
0 Died 
0 Survived &e and well 25 mo. po 
0 Survived Alive and well 26 mo. po 
Mitral valve replacement Survived Alive and well 26 mo. po 
Aortic root replacement Died 
Mitral valve replacement Survived Gve and well 34 mo. po 
Tricuspid valve replacement Died - 
Group II 
9 Allograft PV 277 114 Mitral valve repair 
10 Allograft AV 216 135 0 
11 Allograft PV 190 137 Aortocoronary bypass X2 
12 Altograft AV 164 120 Atrial septal defect closure 
13 Allograft AV 214 125 0 
14 Allograft AV 228 127 Aortic root replacement 
15 Allograft AV 140 87 0 








Alive and well 2 1 mo. po 
- 
Alive and well 8 mo. po 
Alive and well 13 mo. po 
Alive; late repeat AVR 
24 mo. po 
Died 10 mo. po of 
noncardiac causes 
Alive and well 18 mo. po 
findings, techniques and results were noted. Pathologic 
and bacteriologic analyses of operative specimens were 
reviewed. 
The choice of valve substitute was made by the sur- 
geon before beginning the operation. The decision to 
use or not to use an allograft valve was based on the 
surgeon’s experience with and confidence in these ma- 
terials, and did not reflect any other patient selection 
factors such as age, cardiac function, hemodynamic in- 
stability or associated procedures required. In only 1 
case was this decision altered. One patient for whom an 
allograft was intended had an aortic anulus that ex- 
ceeded the size of any available allograft. This patient 
therefore received a porcine valve. For patients in 
whom an allograft valve was selected, an aortic valve 
allograft was used when possible. When no aortic allo- 
graft was available in the correct size, a pulmonary 
valve allograft was used instead. Mechanical or bio- 
prosthetic valves were selected in non-allograft recipi- 
ents based on criteria such as patient age, contraindica- 
tions to anticoagulation, possible desire for pregnancy, 
and ability to comply with a medical regimen. Antibiot- 
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ic coverage was instituted at diagnosis and continued 
for 6 weeks postoperatively. Postoperative data were 
obtained by outpatient follow-up in our clinic, or by 
phone with the patient and the patient’s personal physi- 
cian. No patient was lost to follow-up. 
RESULTS 
Of 15 patients who met the criteria for emergency 
AVR for endocarditis, 12 underwent operation within 
24 hours of diagnosis, all within 48 hours. Eleven pa- 
tients were taken to the operating room immediately 
after cardiac catheterization, echocardiography or com- 
puterized tomography. Data are summarized in Tables 
I and II. Eight patients (group I) underwent AVR with 
a prosthetic valve (4 mechanical, 4 bioprosthetic valves) 
and 7 patients (group II) underwent AVR with a cryo- 
preserved human aortic valve (5) or pulmonic valve (2). 
Group I included 5 men and 3 women and group II 
included 2 men and 5 women. Groups I and II were 
similar in mean age (group I, 55 years; group II, 51 
years), frequency of intravenous drug abuse (group I, 1 
patient; group II, 3 patients), and history of previous 
AVR with a prosthetic valve (group I, 3 patients; group 
II, 2 patients). A comparison of patients with native 
valve endocardi%is to those with prosthetic valve endo- 
carditis is listed in Table III. Cardiopulmonary bypass 
times were significantly longer in patients with pros- 
thetic valve endocarditis, but no other statistically sig- 
nificant differences were found. Additional operative 
findings were septal abscess in 1 group I and 4 group II 
patients, mitral valve endocarditis in 1 group I and 1 
group II patient, atria1 septal defect in 1 group II pa- 
tient, and aorta-right atrium fistula in 1 group II pa- 
tient. All patients had positive blood cultures at the 
time of operation. Cultures of valvar vegetations or 
blood, or both, in group I patients were positive for 
Staphylococcus aureus in 5 patients, and for Strepto- 
coccus sanguis, Streptococcus bovis, and Streptococcus 
hyacis in 1 patient each. Cultures in group II patients 
were positive for Staphylococcus aureus in 3 patients, 
Streptococcus faecalis in 3, and Candida albicans in 1. 
All staphylococcal species were sensitive to methicillin. 
Additional procedures performed in group I patients 
included replacement of the mitral valve (2), tricuspid 
valve (1) and aortic root (1). Additional procedures in 
group II were mitral valve repair (1), aortic root re- 
placement (1 ), atria1 septal defect closure (1) and coro- 
nary artery bypass X 2 (1). Mean duration of cardio- 
pulmonary bypass (group I, 189 minutes); group II, 
204 minutes) and aortic cross-clamping (group I, 108 
minutes; group II, 121 minutes) were not significantly 
different. 
Perioperative deaths occurred in 4 of 8 group 1 pa- 
tients and in 1 of 7 group II patients. Three group II 
patients with septal abscesses required insertion of per- 
TABLE III Comparison of Patients Undergoing Operation for 
Native Versus Prosthetic Valve Infections 
Native Valve Prosthetic Valve 
Infection Infection 
Number of patients 10 5 
Age (years) 53 I 4 54 + 8 
Indications for operation 
Congestive failure 6 3 
Sepsis 1 2 
Cerebral emboli 3 0 
Patients requiring additional procedures 5 3 
Cardiopulmonary bypass duration (min) 169 i- 17 250 k 24* 
Cardiac ischemic duration (min) 105 -+ 10 132 ? 10 
Operative results 
Survived 8 2 
Died 2 3 
Long-term results 
Well without reoparation 7 1 
Well after reoperation 1 0 
Late death 0 1 
*p = 0.02.Values are mean 2 standard error of the mean. 
manent pacemakers for complete heart block. Two had 
documented heart block preoperatively. No other sig- 
nificant complications were encountered. All patients 
with focal neurologic injury attributed to preoperative 
emboli exhibited improvement after AVR, and no new 
neurologic problems were encountered. 
Mean duration of follow-up has been 28 months in 
group I and 18 months in group II. One group II pa- 
tient, who continued to use intravenous drugs, devel- 
oped recurrent endocarditis 6 months after allograft 
AVR. This patient was successfully treated medically, 
and cardiac catheterization demonstrated competence 
of her allograft valve. She presented to another hospital 
18 months after allograft AVR with severe aortic insuf- 
ficiency. At reoperation, she was found to have a perfo- 
ration of 1 valve leaflet. Blood and valve cultures at 
operation were negative. Her allograft was replaced 
with a porcine valve in accordance with the preference 
of the surgeon treating her at that time. One group II 
patient died in a motor vehicle accident 10 months after 
AVR. All other group I and II patients are alive and 
well, without evidence of valve dysfunction. 
DISCUSSION 
The frequency of endocarditis may be increasing, 
perhaps due to nosocomial infections resulting from in- 
vasive procedures, immunosuppressed states and intra- 
venous drug abuse, among other factors. In addition, a 
substantial percentage of all endocarditis is encoun- 
tered among patients with previously inserted prosthetic 
valves. The bacteriologic characteristics of endocarditis 
are changing as well. Although the frequency of Strep- 
tococcus viridans endocarditis appears to be decreasing, 
this may actually reflect an increasing frequency of oth- 
er organisms.9 Thus, the need for operative intervention 
will likely increase as well. Most patients with endocar- 
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ditis are best treated nonoperatively unless there is a 
specific indication for operation. However, endocarditis 
associated with severe aortic insufficiency and conges- 
tive failure is fatal in 40 to 93% of patients without 
surgical treatment. 9 Endocarditis with septic emboli, 
overwhelming sepsis, intracardiac abscess, conduction 
disturbance, resistant organisms, suppurative pericardi- 
tis or clinical deterioration despite appropriate antibiot- 
ics are other indications for AVR. 
When operation is indicated for endocarditis, it is 
preferred that antibiotics be used to control the infec- 
tion, so that valve replacement may have the highest 
probability of success. lo71 However, inappropriate de- 
lay to achieve bacteriologic “cure” may carry excessive 
risk.12 The operative mortality of valve replacement for 
active endocarditis is 3 to 4 times that for controlled 
infection.‘1*13 The patients in this series represent the 
extreme portion of the endocarditis spectrum. All of 
these patients required emergency operation because of 
specific clinical findings (hemodynamic collapse, cere- 
bral emboli or septic shock) that were contraindications 
to even a brief trial of nonoperative therapy. Reports 
of surgical intervention for active endocarditis often 
have included patients who underwent operation after 
lengthy antibiotic therapy14 as well as patients with 
moderate congestive heart failure as an indication for 
operation. l3 Nevertheless, reported operative mortality 
for valve replacement for endocarditis has been as high 
as 30%. 1 lJ3-t6 
Comparison of published series is made difficult by 
the wide differences in definitions. “Early” operations 
for endocarditis have included patients treated for 1 
week to 2 months after diagnosis.t7-l9 Most series de- 
scribing emergency valve replacement for endocarditis 
report high frequencies of death and early reopera- 
tions.13*20J1 However, there are reports of patients un- 
dergoing emergency valve replacement for endocarditis 
with survival of L90%.22p23 
In such an emergency setting, the selection of valve 
replacement may be influenced by perceived difficulties 
related to the patient’s condition and to technical prob- 
lems. Considerations of long-term valve function, he- 
modynamic performance, resistance to reinfection and 
freedom from anticoagulant therapy may be subordi- 
nate to accomplishing an expeditious procedure and im- 
proving the patient’s chances of operative survival. Al- 
though allografts are more resistant to infection, use of 
allografts requires greater ischemic time and more pre- 
cise operative technique. As a result, the use of aortic 
valve allografts for AVR may be questioned. 
The results of this series suggest allografts are ac- 
ceptable replacements even in the most seriously ill pa- 
tients with endocarditis. Bypass and ischemic times 
were not significantly greater in allograft recipients. 
Long-term results of allograft AVR in this setting re- 
main unknown, although our only patient requiring late 
reoperation continued to use intravenous drugs after 
her AVR. The 1 operative death among allograft recip- 
ients occurred in a patient with fungal infection of a 
prosthetic valve, a condition that is fatal in 80 to 90% 
of cases.24,25 
AVR for endocarditis was first described in 196?~~~ 
Allograft AVR for endocarditis was first reported in 
1970.3 In 1984, Ross’s group described aortic root re- 
placement with an allograft for prosthetic valve endo- 
carditis2 Since then, others have established the effica- 
cy of allografts for both freehand AVR and aortic root 
replacement in endocarditis.4-6 The advantages of allo- 
grafts in patients with endocarditis include resistance to 
reinfection, easier management of root abscesses, and 
success in severe endocarditis where prosthetic valves 
have failed.27 These advantages are amplified by the 
excellent performance of allografts with respect to he- 
modynamics, durability and freedom from thromboem- 
bolism. Long-term follow-up after valve replacement 
for active endocarditis is important. The 5-year survival 
in these patients is 40 to 79%, with a reoperation rate 
as high as 13%. 16~19,28 Allografts may improve these 
long-term results. The use of pulmonary valve allo- 
grafts for AVR has rarely been reported.29 Pulmonary 
allografts require more precise technique because they 
are less rigid, and their long-term durability is uncer- 
tain. However, pulmonary allografts may calcify less 
than aortic allografts.30 
In treating endocarditis surgically, the replacement 
material used is only one factor affecting the results. 
Prompt intervention, adequate debridement, oblitera- 
tion of tistulas, resection of mycotic aneurysms, secure 
suture placement and antibiotic treatment are unques- 
tionably of greater importance. The operative outcome 
is also heavily dependent on the patient’s underlying 
condition and left ventricular function. We believe the 
results of this study support the use of allografts for 
emergency AVR for endocarditis. Further use and 
more long-term follow-up are needed to fully evaluate 
the benefits of this approach. 
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